Micronutrients and Child Health Study (MACH)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine to what extent supplementation with zinc and other micronutrients are efficacious in preventing malaria in young Tanzanian children.
| Condition | Intervention | Phase |
|---|---|---|
|
Malaria |
Dietary Supplement: Zinc Dietary Supplement: Vitamins and minerals other than zinc Dietary Supplement: Vitamins plus zinc and other minerals Dietary Supplement: Placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Factorial Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Effects of Supplementation With Zinc and Other Micronutrients on the Health and Development of African Children |
- Febrile malaria episodes [ Time Frame: 60 weeks ] [ Designated as safety issue: No ]
- Haematologic and urinary indicators of micronutrient status [ Time Frame: 30 weeks after start of intervention ] [ Designated as safety issue: Yes ]
- Anthropometric indices [ Time Frame: 57 weeks after start of intervention ] [ Designated as safety issue: No ]
- T cell immune responses to in vitro stimulation with a crude Plasmodium falciparum lysate [ Time Frame: 30 weeks after start of intervention ] [ Designated as safety issue: No ]
- Plasma immunoglobulin concentrations [ Time Frame: 2 weeks after malaria episodes ] [ Designated as safety issue: No ]
| Enrollment: | 612 |
| Study Start Date: | March 2008 |
| Study Completion Date: | March 2009 |
| Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Zinc
|
Dietary Supplement: Zinc
Daily oral supplementation with zinc, 10 mg, for an average of 60 weeks
|
|
Active Comparator: 2
Vitamins and minerals other than zinc
|
Dietary Supplement: Vitamins and minerals other than zinc
Daily supplementation with vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
|
|
Active Comparator: 3
Vitamins plus zinc and other minerals
|
Dietary Supplement: Vitamins plus zinc and other minerals
Daily oral supplementation with zinc, vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
|
|
Placebo Comparator: 4
Placebo for all vitamins and minerals
|
Dietary Supplement: Placebo
Daily oral supplementation with placebo for vitamins and all minerals; for an average of 60 weeks
|
Detailed Description:
Zinc is essential for the functioning of the immune system. Supplementation trials in Asia, Latin America, the Pacific and developed countries have shown that increasing zinc intake has great potential to control common infections in children, but the response to supplementation may be different in Africa, where the primary environmental challenge to children's health is malaria. Simultaneous supplementation with other potentially limiting nutrients may be required to overcome a lack of response when zinc is given alone. The project aims at measuring effects of daily oral supplementation with zinc and other micronutrients, given either alone or in combination, on malaria incidence and nutritional status, and on indicators of immunity.
Eligibility| Ages Eligible for Study: | 6 Months to 60 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Aged 6-60 months
- Permanently residing in the study area
- Being moderately or mildly stunted (height-for-age z-score <-1.5 SD)
- Informed consent from parents or guardians obtained
Exclusion Criteria:
- Severe wasting (weight-for-height z-score <-3 SD)
- Hemoglobin concentration <70 g/L
- Axillary temperature ≥37.50 °C with malaria antigenemia
- Signs and symptoms at randomisation suggesting malaria, hepatitis, HIV/AIDS, tuberculosis, sickle cell disease or other severe condition
- Unable to produce a venous blood sample (>1 mL)
Contacts and Locations| Tanzania | |
| Kilimanjaro Christian Medical Centre | |
| Moshi, Tanzania | |
| Principal Investigator: | Hans Verhoef, PhD | Wageningen University, Cell Biology and Immunology Group |
| Study Chair: | Raimos M Olomi, MD MMed MPH | Kilimanjaro Christian Medical Centre |
| Study Director: | Huub FJ Savelkoul, PhD | Wageningen University, Cell Biology and Immunology Group |
| Study Director: | John F. Shao, MD | Kilimanjaro Christian Medical Centre |
More Information
No publications provided by Wageningen University
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Hans Verhoef, Wageningen University, The Netherlands |
| ClinicalTrials.gov Identifier: | NCT00623857 History of Changes |
| Other Study ID Numbers: | WAO 93-442 |
| Study First Received: | February 14, 2008 |
| Last Updated: | March 3, 2010 |
| Health Authority: | Tanzania: National Institute for Medical Research |
Keywords provided by Wageningen University:
|
Micronutrients Zinc Vitamins Trace elements Minerals Vitamin A Vitamin B1 Vitamin B2 Niacin Vitamin B6 Folic acid Vitamin B12 Vitamin C |
Vitamin D Vitamin E Vitamin K Iron Iodine Copper Selenium Magnesium Calcium Malaria Immunity Anthropometry |
Additional relevant MeSH terms:
|
Malaria Protozoan Infections Parasitic Diseases Vitamin B 12 Vitamin B 6 Riboflavin Thiamine Zinc Micronutrients Vitamins |
Trace Elements Vitamin B Complex Growth Substances Physiological Effects of Drugs Pharmacologic Actions Photosensitizing Agents Radiation-Sensitizing Agents Dermatologic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 23, 2013